End Cash: The amount of cash held by the company for the given period.
TScan Therapeutics, Inc. (TCRX) had End Cash of $159.14M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$2.17M |
|
$-34.13M |
|
-- |
|
$2.17M |
|
$38.42M |
|
$-36.25M |
|
$2.12M |
|
$-34.13M |
|
$-34.13M |
|
$-34.13M |
|
$-34.13M |
|
$-34.13M |
|
$-34.13M |
|
$-36.25M |
|
$-35.57M |
|
129.68M |
|
129.68M |
|
$-0.26 |
|
$-0.26 |
|
| Balance Sheet Financials | |
$254.84M |
|
$8.35M |
|
$77.87M |
|
$332.71M |
|
$29.82M |
|
$32.18M |
|
$92.69M |
|
$122.51M |
|
$210.20M |
|
$210.20M |
|
$210.20M |
|
56.59M |
|
| Cash Flow Statement Financials | |
$-37.59M |
|
$13.53M |
|
$-0.53M |
|
$183.72M |
|
|
End Cash |
$159.14M |
$-24.58M |
|
$3.41M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.55 |
|
-- |
|
-- |
|
0.13 |
|
0.15 |
|
100.00% |
|
-1669.74% |
|
-1669.74% |
|
-- |
|
-1571.95% |
|
-1571.95% |
|
$-39.12M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-16.24% |
|
-16.24% |
|
-10.26% |
|
-14.08% |
|
$3.71 |
|
$-0.30 |
|
$-0.29 |
|